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Background: No randomized or controlled trial has addressed safety or efficacy of the Everolimus eluting platinum chromium stent (Promus 
Element)
Methods: We evaluated outcome of the first 1131 implanted Promus Element stents in the national and complete Swedish Coronary Angiography 
and Angioplasty Registry (SCAAR).
Results: Patients who had received at least one Promus Element stent represented a true all comers population with large proportion of patients 
with acute corornary syndromes. The mean age was 67 years with 23% being women, 19% smokers, 25% diabetes, 36% prior myocardial infarction, 
39% previous PCI and 63% being treated for an acute coronary syndrome. The mean stent diameter was 2.9 mm and mean length 20mm. The 
majority, 46% of stents, were inplanted in the LAD, 13% in a bifurcation and 59% in a B2/C lesion. During a mean follow-up of 6 months there were 
2 cases of stent thrombosis and 8 cases of clinically meaningful restenosis. At the time of the ACC the event rates will be updated with at least 6 
months of follow up in all patients.
Conclusions: The everoluminus eluting platinum chromium stent appear to perform well with a low risk of restenosis and stent thrombosis similar 
to the everolimus eluting Promus and Xience V stents.
